Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cance...( Complete Data to be Submitted for Pr...),Health

Complete Data to be Submitted for Presentation at 2007 San Antonio Breast

Cancer Symposium

REDWOOD CITY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced encouraging results from a study of Oncotype DX in postmenopausal women with node-positive, hormone receptor positive breast cancer conducted by the Southwest Oncology Group (SWOG), a National Cancer Institute clinical trials cooperative group. Oncotype DX is a multi-gene expression test that physicians currently use to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for women with estrogen receptor positive, node-negative breast cancer. This study focused on a different population of patients and results suggest the Oncotype DX test may be useful in predicting survival without recurrence and the benefit of chemotherapy for node-positive breast cancer patients.

For this study, researchers analyzed tumor samples from patients in the SWOG/ Breast Cancer Intergroup of North America trial that evaluated postmenopausal patients with node-positive, hormone receptor positive breast cancer who were treated with chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, followed by tamoxifen) versus tamoxifen alone. Benefit of the addition of chemotherapy was observed in patients with high Oncotype DX Recurrence Scores. However, chemotherapy did not appear to benefit patients with low Oncotype DX Recurrence Scores, despite the presence of positive nodes. These results may be clinically useful in some patients with hormone receptor positive, node-positive breast cancer.

SWOG and Genomic Health plan to submit these data for presentation at the
'/>"/>